9.24
price down icon1.49%   -0.14
after-market Dopo l'orario di chiusura: 9.20 -0.04 -0.43%
loading
Precedente Chiudi:
$9.38
Aprire:
$9.26
Volume 24 ore:
1.31M
Relative Volume:
0.46
Capitalizzazione di mercato:
$1.05B
Reddito:
-
Utile/perdita netta:
$-294.51M
Rapporto P/E:
-2.5955
EPS:
-3.56
Flusso di cassa netto:
$-244.42M
1 W Prestazione:
-1.70%
1M Prestazione:
-13.08%
6M Prestazione:
-32.65%
1 anno Prestazione:
-78.88%
Intervallo 1D:
Value
$9.12
$9.425
Intervallo di 1 settimana:
Value
$8.95
$9.5993
Portata 52W:
Value
$6.36
$47.45

Dyne Therapeutics Inc Stock (DYN) Company Profile

Name
Nome
Dyne Therapeutics Inc
Name
Telefono
(781) 786-8230
Name
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Name
Dipendente
192
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
DYN's Discussions on Twitter

Confronta DYN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
DYN
Dyne Therapeutics Inc
9.24 1.33B 0 -294.51M -244.42M -3.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-24 Iniziato Bernstein Mkt Perform
2025-06-11 Ripresa Raymond James Outperform
2025-06-02 Ripresa Oppenheimer Outperform
2025-05-29 Iniziato Evercore ISI Outperform
2025-03-12 Iniziato BMO Capital Markets Outperform
2025-03-07 Iniziato Scotiabank Sector Outperform
2024-12-13 Iniziato Robert W. Baird Outperform
2024-11-26 Iniziato RBC Capital Mkts Outperform
2024-10-24 Downgrade JP Morgan Overweight → Neutral
2024-05-21 Reiterato Chardan Capital Markets Buy
2024-04-30 Iniziato Morgan Stanley Overweight
2024-02-20 Iniziato H.C. Wainwright Buy
2023-02-27 Aggiornamento Raymond James Outperform → Strong Buy
2023-02-15 Iniziato Oppenheimer Outperform
2023-01-26 Iniziato Guggenheim Buy
2022-07-20 Iniziato Chardan Capital Markets Buy
2022-07-12 Iniziato Raymond James Outperform
2020-10-12 Iniziato JP Morgan Overweight
2020-10-12 Iniziato Jefferies Buy
2020-10-12 Iniziato Piper Sandler Overweight
2020-10-12 Iniziato Stifel Buy
Mostra tutto

Dyne Therapeutics Inc Borsa (DYN) Ultime notizie

pulisher
Jul 24, 2025

Dyne Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Dyne Therapeutics Inc. stockFree Stock Market Return Analysis - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Dyne Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - WV News

Jul 22, 2025
pulisher
Jul 21, 2025

Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 18, 2025

Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat

Jul 18, 2025
pulisher
Jul 16, 2025

Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey

Jul 16, 2025
pulisher
Jul 16, 2025

Dyne Therapeutics (DYN) Stock Rises as CEO Increases Stake - GuruFocus

Jul 16, 2025
pulisher
Jul 16, 2025

Dyne shares up after CEO buys stock (DYN:NASDAQ) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Former Biogen VP Who Led SPINRAZA Success Joins Satellos to Advance DMD Treatment - Stock Titan

Jul 16, 2025
pulisher
Jul 16, 2025

Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Strategic Confidence in Dyne Therapeutics: Insider Backing and Breakthroughs in Rare Disease Therapies - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

DYN CEO Makes Significant Stock Purchase, Shares Rise | DYN Stoc - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com

Jul 15, 2025
pulisher
Jul 12, 2025

Evercore ISI Analyst Lowers Dyne Therapeutics Price Target to $41, Maintains Outperform Rating - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT - Yahoo Finance

Jul 12, 2025
pulisher
Jul 11, 2025

Dyne Therapeutics (DYN) Sees Price Target Reduced by Evercore IS - GuruFocus

Jul 11, 2025
pulisher
Jul 10, 2025

Dyne Therapeutics’ DYNE-251 Study Update: A Potential Game-Changer for Duchenne Muscular Dystrophy - TipRanks

Jul 10, 2025
pulisher
Jul 08, 2025

RBC Capital Sticks to Their Buy Rating for Dyne Therapeutics (DYN) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 07, 2025

Dyne Therapeutics shares rise 2.08% after-hours following RBC's price target cut to $25. - AInvest

Jul 07, 2025
pulisher
Jul 05, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jul 05, 2025
pulisher
Jul 04, 2025

(DYN) Trading Report - news.stocktradersdaily.com

Jul 04, 2025
pulisher
Jul 04, 2025

Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 04, 2025
pulisher
Jul 03, 2025

ATTENTION DYN Shareholders: Lost Money on Dyne Therapeutics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

Petri Dish: ProFound’s Novartis deal worth $750M, Dyne secures debt - The Business Journals

Jul 03, 2025
pulisher
Jul 02, 2025

Dyne Therapeutics Announces Closing of Public Offering of Common - GuruFocus

Jul 02, 2025
pulisher
Jul 02, 2025

Dyne Therapeutics' $230M Capital Injection: A Strategic Gamble in Rare Neuromuscular Disorders? - AInvest

Jul 02, 2025
pulisher
Jul 02, 2025

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times

Jul 02, 2025
pulisher
Jul 02, 2025

Dyne Therapeutics Closes $230 Million Public Offering of Common Stock - Quiver Quantitative

Jul 02, 2025
pulisher
Jul 02, 2025

Dyne Therapeutics Announces Closing of Public Offering of - GlobeNewswire

Jul 02, 2025
pulisher
Jul 02, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jul 02, 2025
pulisher
Jul 01, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Connect - ACCESS Newswire

Jul 01, 2025
pulisher
Jul 01, 2025

Shareholders Alert: Investigation Into Dyne Therapeutics, Inc. (DYN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jul 01, 2025
pulisher
Jul 01, 2025

Dyne Therapeutics (DYN) Launches $200 Million Public Offering - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Jul 01, 2025
pulisher
Jul 01, 2025

Dyne Therapeutics slides on $200 mln equity raise - TradingView

Jul 01, 2025
pulisher
Jul 01, 2025

Dyne Therapeutics, Inc. (DYN) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire

Jul 01, 2025

Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):